Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jan 2025 Status changed from recruiting to discontinued.
09 Dec 2024 According to Relmada Therapeutics, Inc., the company will discontinue the Reliance II and Relight Phase 3 studies of the REL-1017 program following the recent evaluation of the full dataset from the Reliance II Phase 3 study by the data monitoring committee (DMC).
07 Aug 2024 According to a Relmada Therapeutics media release, company expects to complete enrollment in Reliance II by year-end 2024, to be followed by Relight 6-months after that.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com